ketorolac has been researched along with Abdominal Migraine in 43 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous ketorolac is commonly used for treating migraine headaches in children." | 9.51 | Intranasal ketorolac versus intravenous ketorolac for treatment of migraine headaches in children: A randomized clinical trial. ( Babineau, SE; Carter, RC; Chernick, LS; Dayan, PS; DePeter, KC; Fan, W; Friedman, BW; Gonzalez, AE; Kwok, MY; Lubell, TR; McLaren, SH; Roskind, CG; Tsze, DS, 2022) |
| "We compare the effectiveness of intravenous ketorolac and intravenous prochlorperazine in the treatment of pediatric migraine headaches." | 9.11 | Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. ( Anderson, AC; Brousseau, DC; Duffy, SJ; Linakis, JG, 2004) |
| "Intravenous ketorolac is commonly used for treating migraine headaches in children." | 5.51 | Intranasal ketorolac versus intravenous ketorolac for treatment of migraine headaches in children: A randomized clinical trial. ( Babineau, SE; Carter, RC; Chernick, LS; Dayan, PS; DePeter, KC; Fan, W; Friedman, BW; Gonzalez, AE; Kwok, MY; Lubell, TR; McLaren, SH; Roskind, CG; Tsze, DS, 2022) |
| "The objective of this study was to assess the efficacy and safety of a common monotherapy (intravenous [iv] metoclopramide) compared to a combination strategy (adding iv ketorolac to metoclopramide) in children presenting for acute treatment of migraine headache in the emergency department (ED)." | 5.51 | A randomized trial of ketorolac and metoclopramide for migraine in the emergency department. ( Ali, S; Johnson, DW; Newton, AS; Richer, LP; Rosychuk, RJ; Rowe, BH, 2022) |
| " Compared to other active drugs, it only showed a lower significant effect compared with granisetron regarding headache change while it showed significantly higher effects only with placebo in both rescue medication needs and headache-free symptoms and valproate in only rescue medication need." | 5.41 | The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. ( Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW, 2023) |
| "This review was designated to evaluate the efficacy of parenteral ketorolac in treating acute migraine headache." | 5.22 | Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis. ( Abu Bakar, MA; Baharuddin, KA; Norhayati, MN; Nurathirah, MN; Yazid, MB, 2022) |
| "We compare the effectiveness of intravenous ketorolac and intravenous prochlorperazine in the treatment of pediatric migraine headaches." | 5.11 | Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. ( Anderson, AC; Brousseau, DC; Duffy, SJ; Linakis, JG, 2004) |
| "In treatment of refractory migraine headache, CAMBIA® may provide similar benefits as IM ketorolac without increasing the risk of treatment failure, major bleeding, or cardiovascular events." | 2.94 | IM ketorolac vs diclofenac potassium powder for oral solution for the acute treatment of severe migraine: a randomized controlled trial. ( Cheng, J; Engel, ER, 2020) |
| "Only ketorolac NS was superior to placebo for 24-hour (ketorolac: 35." | 2.82 | A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine. ( Dash, PD; Gelaye, B; Kurth, T; Nitchie, H; Peterlin, BL; Rao, AS, 2016) |
| "Pediatric migraine is a common, chronic, and disabling neurological disorder in children and adolescents." | 2.66 | Intravenous Migraine Treatment in Children and Adolescents. ( Hershey, AD; Kabbouche, M; Maconochie, I; Murphy, B; Qaiser, S; Werner, K, 2020) |
| "Acute migraine headaches are common emergency department presentations, and despite evidence for various treatments, there is conflicting evidence regarding the use of KET." | 2.49 | Ketorolac in the treatment of acute migraine: a systematic review. ( Campbell, S; Doran, S; Kokotillo, A; Rowe, BH; Taggart, E; Villa-Roel, C, 2013) |
| "Meperidine was less effective than dihydroergotamine at providing headache relief (OR=0." | 2.44 | The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. ( Friedman, BW; Friedman, MS; Hochberg, ML; Kapoor, A; Rowe, BH, 2008) |
| "Treatment of pediatric migraine includes an individually tailored regimen of both nonpharmacologic and pharmacologic measures." | 2.43 | Symptomatic treatment of migraine in children: a systematic review of medication trials. ( Berger, MY; Bruijn, JK; Damen, L; Koes, BW; Passchier, J; Verhagen, AP, 2005) |
| "To compare pediatric migraine treatment efficacy in the emergency department before and after the implementation of a comprehensive migraine initiative, consisting of a standardized treatment protocol, provider educational series and standardized physician documentation template." | 1.56 | Comprehensive Migraine Initiative in the Pediatric Emergency Department Improves Treatment Outcomes. ( Oakley, CB; Skora, CE; Worden, LT, 2020) |
| "Patients with episodic and chronic migraine who experienced continuous and prolonged attacks for more than 72 hours were treated with dexamethasone (4 mg orally twice daily for 3 days), ketorolac (60 mg intramuscularly), bilateral nerve blocks (1-2% lidocaine, 0." | 1.56 | Unrecognized challenges of treating status migrainosus: An observational study. ( Ashina, S; Burstein, R; Chua, A; Grosberg, B; Iljazi, A; Melo-Carrillo, A; Rich-Fiondella, R; Veronesi, M, 2020) |
| "We calculated the percent of migraine patients given each treatment in each time period." | 1.51 | ED treatment of migraine patients has changed. ( Allegra, JR; Eskin, B; Richman, P; Ruzek, M, 2019) |
| "Migraine headaches are common in the pediatric emergency department." | 1.48 | Relative Effectiveness of Dopamine Antagonists for Pediatric Migraine in the Emergency Department. ( Fu, R; Hansen, ML; Laurie, A; Ma, OJ; Meckler, GD; Pacheco, S; Sheridan, DC, 2018) |
| "When ibuprofen alone was administered, pain scores equal to or lower than 5/10 were associated with the greatest sensitivity and specificity for discharge." | 1.46 | Factors Associated With Discharge After Initial Emergency Treatment of Pediatric Migraine. ( Aravamuthan, BR; Mar, SS; Williams, KG, 2017) |
| " In this study, we formulate a Zolmitriptan (ZT) & ketorolac tromethamine (KT) loaded thermo reversible in-situ mucoadhesive intranasal gel (TMISG) formulation which gels at the nasal mucosal temperature and contains a bioadhesive polymer (Xyloglucan) that lengthens the residence time will enhance the bioavailability of the combinational drugs." | 1.42 | Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design. ( Garg, T; Goyal, AK; Kumar, A; Rath, G; Sarma, GS, 2015) |
| "Intravenous migraine therapy reduces PTH pain scores for children presenting within 14 days after mTBI." | 1.42 | Intravenous migraine therapy in children with posttraumatic headache in the ED. ( Byczkowski, T; Chan, S; Kurowski, B; Timm, N, 2015) |
| "If you vomit with migraines, get full-blown migraines upon awakening, or want rapid relief without injections, consider a nasal spray." | 1.39 | Nasal sprays for the treatment of migraine. ( Tepper, DE, 2013) |
| "The diagnosis of migraine was confirmed using predefined criteria." | 1.35 | Utilization, diagnosis, treatment and cost of migraine treatment in the emergency department. ( Feldon, S; Fisher, S; Friedman, D; Holloway, R, 2009) |
| "A pharmacological model of migraine is described using ultrasound vocalization (USV) of rats following central inflammation-induced sensitization to tactile stimulation." | 1.35 | Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo. ( Martino, G; Perkins, MN, 2008) |
| "Ketorolac IM was compared to DHE and metoclopramide IV in migraine patients whose regular abortive medication had failed and who presented to a headache clinic for acute treatment." | 1.28 | Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. ( Klapper, JA; Stanton, JS, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (18.60) | 18.2507 |
| 2000's | 8 (18.60) | 29.6817 |
| 2010's | 16 (37.21) | 24.3611 |
| 2020's | 11 (25.58) | 2.80 |
| Authors | Studies |
|---|---|
| Tsze, DS | 1 |
| Lubell, TR | 1 |
| Carter, RC | 1 |
| Chernick, LS | 1 |
| DePeter, KC | 1 |
| McLaren, SH | 1 |
| Kwok, MY | 1 |
| Roskind, CG | 1 |
| Gonzalez, AE | 1 |
| Fan, W | 1 |
| Babineau, SE | 1 |
| Friedman, BW | 5 |
| Dayan, PS | 1 |
| Atif, H | 1 |
| McGhee, J | 1 |
| Nurathirah, MN | 1 |
| Yazid, MB | 1 |
| Norhayati, MN | 1 |
| Baharuddin, KA | 1 |
| Abu Bakar, MA | 1 |
| Richer, LP | 1 |
| Ali, S | 1 |
| Johnson, DW | 1 |
| Rosychuk, RJ | 1 |
| Newton, AS | 1 |
| Rowe, BH | 3 |
| Abdelmonem, H | 1 |
| Abdelhay, HM | 1 |
| Abdelwadoud, GT | 1 |
| Alhosini, ANM | 1 |
| Ahmed, AE | 1 |
| Mohamed, SW | 1 |
| Al-Dardery, NM | 1 |
| Abd-ElGawad, M | 1 |
| Kamel, MA | 1 |
| Skora, CE | 1 |
| Worden, LT | 1 |
| Oakley, CB | 1 |
| Engel, ER | 1 |
| Cheng, J | 1 |
| Iljazi, A | 1 |
| Chua, A | 1 |
| Rich-Fiondella, R | 1 |
| Veronesi, M | 1 |
| Melo-Carrillo, A | 1 |
| Ashina, S | 1 |
| Burstein, R | 1 |
| Grosberg, B | 1 |
| Werner, K | 1 |
| Qaiser, S | 1 |
| Kabbouche, M | 1 |
| Murphy, B | 1 |
| Maconochie, I | 1 |
| Hershey, AD | 1 |
| Kannikeswaran, N | 1 |
| Desai, L | 1 |
| Farooqi, A | 1 |
| Sivaswamy, L | 1 |
| Wells, S | 1 |
| Stiell, IG | 1 |
| Vishnyakova, E | 1 |
| Lun, R | 1 |
| Nemnom, MJ | 1 |
| Perry, JJ | 1 |
| Ruzek, M | 1 |
| Richman, P | 1 |
| Eskin, B | 1 |
| Allegra, JR | 1 |
| Khazaei, M | 1 |
| Hosseini Nejad Mir, N | 1 |
| Yadranji Aghdam, F | 1 |
| Taheri, M | 1 |
| Ghafouri-Fard, S | 1 |
| Tepper, DE | 1 |
| Garber, L | 3 |
| Yoon, A | 1 |
| Solorzano, C | 1 |
| Wollowitz, A | 1 |
| Esses, D | 1 |
| Bijur, PE | 1 |
| Gallagher, EJ | 3 |
| Factor, SA | 1 |
| Jankovic, J | 1 |
| Kumar, A | 1 |
| Garg, T | 1 |
| Sarma, GS | 1 |
| Rath, G | 1 |
| Goyal, AK | 1 |
| Chan, S | 1 |
| Kurowski, B | 1 |
| Byczkowski, T | 1 |
| Timm, N | 1 |
| Kaar, CR | 1 |
| Gerard, JM | 1 |
| Nakanishi, AK | 1 |
| Aravamuthan, BR | 1 |
| Mar, SS | 1 |
| Williams, KG | 1 |
| Rao, AS | 1 |
| Gelaye, B | 1 |
| Kurth, T | 1 |
| Dash, PD | 1 |
| Nitchie, H | 1 |
| Peterlin, BL | 1 |
| Sheridan, DC | 1 |
| Laurie, A | 1 |
| Pacheco, S | 1 |
| Fu, R | 1 |
| Hansen, ML | 1 |
| Ma, OJ | 1 |
| Meckler, GD | 1 |
| Kapoor, A | 1 |
| Friedman, MS | 1 |
| Hochberg, ML | 1 |
| Peroutka, SJ | 1 |
| Friedman, D | 1 |
| Feldon, S | 1 |
| Holloway, R | 1 |
| Fisher, S | 1 |
| Sokolov, AY | 1 |
| Lyubashina, OA | 1 |
| Panteleev, SS | 1 |
| Chizh, BA | 1 |
| Keller, DL | 1 |
| Taggart, E | 1 |
| Doran, S | 1 |
| Kokotillo, A | 1 |
| Campbell, S | 1 |
| Villa-Roel, C | 1 |
| Meredith, JT | 1 |
| Wait, S | 1 |
| Brewer, KL | 1 |
| Brousseau, DC | 1 |
| Duffy, SJ | 1 |
| Anderson, AC | 1 |
| Linakis, JG | 1 |
| Damen, L | 1 |
| Bruijn, JK | 1 |
| Verhagen, AP | 1 |
| Berger, MY | 1 |
| Passchier, J | 1 |
| Koes, BW | 1 |
| Martino, G | 1 |
| Perkins, MN | 1 |
| Davis, CP | 2 |
| Torre, PR | 2 |
| Williams, C | 1 |
| Gray, C | 1 |
| Barrett, K | 1 |
| Krucke, G | 1 |
| Peake, D | 1 |
| Bass, B | 2 |
| Kumar, KL | 1 |
| Mignot, G | 1 |
| Kopp, C | 1 |
| Lobo, BL | 1 |
| Landy, S | 1 |
| Schafer, NC | 1 |
| Dave, B | 1 |
| Seim, MB | 1 |
| March, JA | 1 |
| Dunn, KA | 1 |
| Larkin, G | 1 |
| Morgenstern, LB | 1 |
| Huber, JC | 1 |
| Luna-Gonzales, H | 1 |
| Saldin, KR | 1 |
| Grotta, JC | 1 |
| Shaw, SG | 1 |
| Knudson, L | 1 |
| Frankowski, RF | 1 |
| Klapper, JA | 1 |
| Stanton, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Nasal Migraine Cocktail Used In Pediatric Emergency Department: A Clinical Trial[NCT06083571] | Phase 2 | 120 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine[NCT02664116] | Phase 4 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)[NCT01807234] | Phase 4 | 72 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| A Randomized Double-blind Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache[NCT03472872] | Phase 4 | 500 participants (Actual) | Interventional | 2017-09-05 | Terminated (stopped due to no longer recruiting or studying) | ||
| Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department[NCT03576820] | Phase 3 | 50 participants (Anticipated) | Interventional | 2018-10-15 | Recruiting | ||
| A Randomized Double Blinded Study Comparing Use of Prochlorperazine Versus Prochlorperazine and Ketorolac in the Treatment of Pediatric Migraine in the Emergency Department[NCT01534806] | Phase 4 | 0 participants (Actual) | Interventional | 2012-01-31 | Withdrawn (stopped due to Drug is backordered;) | ||
| Improving the Headache Management Care in the Emergency Unit by Using a Biological Marker: S100B Protein.[NCT03490500] | 63 participants (Actual) | Observational | 2018-10-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Ketorolac/ Placebo | 72.5 |
| Sumatriptan/ Placebo | 69.4 |
| Ketorolac Placebo/ Sumatriptan Placebo | 38.8 |
5) Absence of allodynia The presence of allodynia was assessed based on a series of 8 questions inquiring as to the presence of allodynia. Participants answering 2 or more questions positively were considered to have allodynia. (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 70.5 |
| Sumatriptan/ Placebo | 75.5 |
| Ketorolac Placebo/ Sumatriptan Placebo | 69.0 |
4) Defined as reduction of nausea to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 82.7 |
| Sumatriptan/ Placebo | 74.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 66.0 |
3) Defined as reduction of phonophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 75.0 |
| Sumatriptan/Placebo | 66.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 56.0 |
2) Defined as reduction of photophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 65.4 |
| Sumatriptan/ Placebo | 64.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 46.0 |
1) Pain Freedom: Pain Freedom at 2 hours is defined as being free of pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 43.1 |
| Sumatriptan/Placebo | 36.7 |
| Ketorolac Placebo/ Sumatriptan Placebo | 18.4 |
Participants' self-assessment of disability was assessed using 4-point scales (none, mild, moderate, and severe). A binary outcome variable was created grouping none and mild vs moderate to severe. . (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 1.9 |
| Sumatriptan/ Placebo | 8.1 |
| Ketorolac Placebo/ Sumatriptan Placebo | 10.2 |
8) 24 and 48 hours sustained pain freedom (SPF); Defined as the reduction of pain to none. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain freedom | 48 hour sustained pain freedom | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 12.2 |
| Ketorolac/ Placebo | 35.3 | 33.3 |
| Sumatriptan/ Placebo | 22.4 | 18.4 |
7) 24 and 48 hours sustained pain relief (SPR) Defined as the reduction of pain to none or mild from moderate or severe, on a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain relief | 48 hour sustained pain relief | |
| Ketorolac Placebo/ Sumatriptan Placebo | 20.4 | 20.4 |
| Ketorolac/ Placebo | 49.0 | 49.0 |
| Sumatriptan/ Placebo | 40.8 | 30.6 |
9) The time, in minutes, will be measured from the time study drug is taken to the time when significant pain relief is first observed and maintained through 2 hours with no rescue medication use at or prior to this point. (NCT01807234)
Timeframe: following each treated migraine attack
| Intervention | percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| 10 minutes | 15 minutes | 20 minutes | 30 minutes | 1 hour | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 14.3 | 22.4 | 26.5 | 32.6 |
| Ketorolac/ Placebo | 15.7 | 35.3 | 43.1 | 54.9 | 58.8 |
| Sumatriptan/ Placebo | 14.3 | 36.0 | 44.9 | 53.1 | 57.1 |
8 reviews available for ketorolac and Abdominal Migraine
| Article | Year |
|---|---|
Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis.
Topics: Caffeine; Dexamethasone; Diclofenac; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Pain; Ph | 2022 |
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea | 2023 |
Intravenous Migraine Treatment in Children and Adolescents.
Topics: Administration, Intravenous; Adolescent; Akathisia, Drug-Induced; Anesthetics, Local; Anti-Inflammat | 2020 |
The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Dihydroergota | 2008 |
2008: the year in review.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Benzopyrans; Clinic | 2009 |
Ketorolac in the treatment of acute migraine: a systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Databases, Bibliographic; Humans; Ketorolac; Migraine Disor | 2013 |
Ketorolac in the treatment of acute migraine: a systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Databases, Bibliographic; Humans; Ketorolac; Migraine Disor | 2013 |
Ketorolac in the treatment of acute migraine: a systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Databases, Bibliographic; Humans; Ketorolac; Migraine Disor | 2013 |
Ketorolac in the treatment of acute migraine: a systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Databases, Bibliographic; Humans; Ketorolac; Migraine Disor | 2013 |
Symptomatic treatment of migraine in children: a systematic review of medication trials.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Controlled Clinical Tr | 2005 |
Recent advances in the acute management of migraine and cluster headaches.
Topics: Analgesics; Butorphanol; Capsaicin; Cluster Headache; Dihydroergotamine; Humans; Ketorolac; Metoclop | 1994 |
11 trials available for ketorolac and Abdominal Migraine
| Article | Year |
|---|---|
Intranasal ketorolac versus intravenous ketorolac for treatment of migraine headaches in children: A randomized clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Double-Blind Method; Humans; Ketorolac; Migraine Dis | 2022 |
A randomized trial of ketorolac and metoclopramide for migraine in the emergency department.
Topics: Adolescent; Child; Double-Blind Method; Emergency Service, Hospital; Headache; Humans; Ketorolac; Me | 2022 |
IM ketorolac vs diclofenac potassium powder for oral solution for the acute treatment of severe migraine: a randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Adult; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Meth | 2020 |
Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: a prospective double-blind randomized clinical trial.
Topics: Administration, Intravenous; Adult; Analgesics; Chlorpromazine; Dexamethasone; Double-Blind Method; | 2019 |
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Double-Blind Method; | 2014 |
A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Disability Evaluation; Double-Bl | 2016 |
A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine.
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind | 2003 |
Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Child; Double-Blind Method; Female | 2004 |
Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Child; Double-Blind Method; Female | 2004 |
Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Child; Double-Blind Method; Female | 2004 |
Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Child; Double-Blind Method; Female | 2004 |
Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients.
Topics: Adult; Analgesics, Non-Narcotic; Double-Blind Method; Drug Combinations; Female; Humans; Ionophores; | 1995 |
Ketorolac as a rapid and effective treatment of migraine headache: evaluations by patients.
Topics: Acute Disease; Adult; Analgesics; Body Weight; Emergency Service, Hospital; Female; Humans; Injectio | 1993 |
Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; | 1998 |
24 other studies available for ketorolac and Abdominal Migraine
| Article | Year |
|---|---|
Randomized IV metoclopramide vs IV ketorolac in treatment of acute primary headache.
Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Headache; Humans; Ketorola | 2022 |
Comprehensive Migraine Initiative in the Pediatric Emergency Department Improves Treatment Outcomes.
Topics: Adolescent; Clinical Protocols; Emergency Service, Hospital; Female; Humans; Ketorolac; Magnesium Su | 2020 |
Unrecognized challenges of treating status migrainosus: An observational study.
Topics: Adult; Dexamethasone; Female; Humans; Ketorolac; Male; Middle Aged; Migraine Disorders; Nerve Block; | 2020 |
Effectiveness of Standard Combination Therapy in Pediatric Migraine.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Diphenhydramine; Dopamine | 2021 |
Optimal management strategies for primary headache in the emergency department.
Topics: Adult; Emergency Service, Hospital; Female; Headache; Humans; Ketorolac; Metoclopramide; Migraine Di | 2021 |
ED treatment of migraine patients has changed.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dexamethasone; Dopamine Antago | 2019 |
Nasal sprays for the treatment of migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Ketorolac; Migraine Disorders; Nasal Sprays; Trypta | 2013 |
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Female; Humans; Ketorolac; M | 2014 |
Author response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Antimanic Agents; Female; Humans; Ketorolac; M | 2014 |
Author response.
Topics: Authorship; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Valproic Acid | 2014 |
Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design.
Topics: Adhesives; Administration, Intranasal; Animals; Disease Management; Drug Delivery Systems; Gels; Ket | 2015 |
Intravenous migraine therapy in children with posttraumatic headache in the ED.
Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Brain Injuries; | 2015 |
The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dihydroergotamine; Diphenhydramine | 2016 |
Factors Associated With Discharge After Initial Emergency Treatment of Pediatric Migraine.
Topics: Administration, Intranasal; Administration, Intravenous; Administration, Oral; Adolescent; Analgesic | 2017 |
Relative Effectiveness of Dopamine Antagonists for Pediatric Migraine in the Emergency Department.
Topics: Adolescent; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Child; Cohort Studies; Dopa | 2018 |
Utilization, diagnosis, treatment and cost of migraine treatment in the emergency department.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Clinical Laboratory Techniques; Diagnos | 2009 |
Neurophysiological markers of central sensitisation in the trigeminal pathway and their modulation by the cyclo-oxygenase inhibitor ketorolac.
Topics: Animals; Biomarkers; Cyclooxygenase Inhibitors; Disease Models, Animal; Dura Mater; Electric Stimula | 2010 |
Triptan therapy in migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Indomethacin; Injections, Intravenous; Ket | 2010 |
Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diazepam; Diseas | 2008 |
Drug therapy of migraine.
Topics: Analgesics; Emergencies; Humans; Ketorolac; Migraine Disorders; Tolmetin | 1994 |
Recommendations for the emergency treatment of migraine headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dexamethasone; Dihydroergotamine; Emergency Me | 1994 |
Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches.
Topics: Analgesics, Non-Narcotic; Antipsychotic Agents; Female; Humans; Infusions, Intravenous; Ketorolac; M | 1999 |
Headache in the emergency department.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Diagnosis, Differential; Drug T | 2001 |
Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Drug Therapy, Combination; Humans; Ketor | 1991 |